[HTML][HTML] SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons
New England Journal of Medicine, 2022•Mass Medical Soc
In Vitro Neutralization of Omicron Variant Serum from vaccinated persons was assayed for
ability to neutralize the omicron variant of SARS-CoV-2. Persons who had received two
doses of the BNT162b2, mRNA-1273, or ChAdOx1-S vaccine had serum that poorly
neutralized omicron, but those who had recovered from infection and were then vaccinated
or who had been vaccinated and had breakthrough infection had high levels of neutralizing
activity.
ability to neutralize the omicron variant of SARS-CoV-2. Persons who had received two
doses of the BNT162b2, mRNA-1273, or ChAdOx1-S vaccine had serum that poorly
neutralized omicron, but those who had recovered from infection and were then vaccinated
or who had been vaccinated and had breakthrough infection had high levels of neutralizing
activity.
In Vitro Neutralization of Omicron Variant
Serum from vaccinated persons was assayed for ability to neutralize the omicron variant of SARS-CoV-2. Persons who had received two doses of the BNT162b2, mRNA-1273, or ChAdOx1-S vaccine had serum that poorly neutralized omicron, but those who had recovered from infection and were then vaccinated or who had been vaccinated and had breakthrough infection had high levels of neutralizing activity.
The New England Journal Of Medicine